文献速递慢阻肺肺栓塞与肺血管病

COPD血管功能障碍机制及新型可溶性环氧化物水解酶抑制剂在吸烟者中的效应

Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
PubMed 文献 · Chest · 2016-11-21

本研究探讨吸烟和慢阻肺(COPD)患者内皮源性环氧二十碳三烯酸(EET)介导的血管内皮功能是否受损,并评估可溶性环氧化物水解酶抑制剂GSK2256294的改善作用。通过前臂体积描记法和体外血管实验,发现COPD患者和超重吸烟者存在EET介导的血管舒张功能减退,而GSK2256294在体外和I期临床试验中可改善该功能障碍。

要点

  • COPD患者和超重吸烟者存在EET介导的内皮依赖性血管舒张功能受损。
  • GSK2256294在体外可增强EET介导的血管舒张并改善缓激肽反应。
  • I期临床试验中单次和慢性给予GSK2256294均改善健康超重吸烟者的缓激肽反应。

核心结论

  • GSK2256294可减轻吸烟相关的EET介导的内皮功能障碍,提示对COPD患者可能有潜在治疗获益。

研究设计与样本

  • 研究纳入12例COPD患者、11例超重吸烟者及两个匹配对照组,采用前臂体积描记法评估EET释放。
  • 体外评估GSK2256294对人阻力动脉EET介导血管舒张的影响。
  • 在健康超重吸烟者中开展I期临床试验评估GSK2256294的体内效应。

主要发现

  • 与对照组相比,COPD患者缓激肽诱导的血管舒张降低(P = .005)。
  • COPD患者氟康唑对缓激肽诱导血管舒张的效应减弱(P = .03)。
  • COPD患者基础EET/二羟基环氧二十碳三烯酸比值呈降低趋势(P = .08)。
  • 超重吸烟者中观察到类似模式。
  • 体外10 μM GSK2256294使11,12-EET介导的最大舒张从72.6% ± 6.2%增至90% ± 4.2%,并改变缓激肽EC50(-8.33 ± 0.172 logM vs -8.10 ± 0.118 logM;P = .001)。

关键数值与推荐

  • 体外10 μM GSK2256294增加11,12-EET介导的血管舒张(90% ± 4.2% vs 72.6% ± 6.2%最大舒张)。
  • 体内18 mg GSK2256294使缓激肽最大反应从给药前338% ± 46%升至单次给药后566% ± 110%(P = .02)及慢性给药后503% ± 123%(P = .003)。

临床怎么用

  • GSK2256294可能作为改善COPD患者吸烟相关内皮功能障碍的潜在治疗药物,尚需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Smoking and COPD are risk factors for cardiovascular disease, and the pathogenesis may involve endothelial dysfunction. We tested the hypothesis that endothelium-derived epoxyeicosatrienoic acid (EET)-mediated endothelial function is impaired in patients with COPD and that a novel soluble epoxide hydrolase inhibitor, GSK2256294, attenuates EET-mediated endothelial dysfunction in human resistance vessels both in vitro and in vivo. METHODS: Endogenous and stimulated endothelial release of EETs was assessed in 12 patients with COPD, 11 overweight smokers, and two matched control groups, using forearm plethysmography with intraarterial infusions of fluconazole, bradykinin, and the combination. The effects of GSK2256294 on EET-mediated vasodilation in human resistance arteries were assessed in vitro and in vivo in a phase I clinical trial in healthy overweight smokers. RESULTS: Compared with control groups, there was reduced vasodilation with bradykinin (P = .005), a blunted effect of fluconazole on bradykinin-induced vasodilation (P = .03), and a trend toward reduced basal EET/dihydroxyepoxyeicosatrienoic acid ratio in patients with COPD (P = .08). A similar pattern was observed in overweight smokers. In vitro, 10 μM GSK2256294 increased 11,12-EET-mediated vasodilation compared with vehicle (90% ± 4.2% vs 72.6% ± 6.2% maximal dilatation) and shifted the bradykinin half-maximal effective concentration (EC50) (-8.33 ± 0.172 logM vs -8.10 ± 0.118 logM; P = .001 for EC50). In vivo, 18 mg GSK2256294 improved the maximum bradykinin response from 338% ± 46% before a dose to 566% ± 110% after a single dose (P = .02) and to 503% ± 123% after a chronic dose (P = .003). CONCLUSIONS: GSK2256294 attenuates smoking-related EET-mediated endothelial dysfunction, suggesting potential therapeutic benefits in patients with COPD. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01762774; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Yang L, Cheriyan J, Gutterman DD, et al. Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers. Chest. 2016. PMID: 27884766. doi:10.1016/j.chest.2016.10.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。